Affordable Access

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine.

Authors
  • Kurtis, J D
  • Hollingdale, M R
  • Luty, A J
  • Lanar, D E
  • Krzych, U
  • Duffy, P E
Type
Published Article
Journal
Trends in Parasitology
Publisher
Elsevier
Publication Date
May 01, 2001
Volume
17
Issue
5
Pages
219–223
Identifiers
PMID: 11323304
Source
Medline
License
Unknown

Abstract

A vaccine is urgently needed to stem the global resurgence of Plasmodium falciparum malaria. Vaccines targeting the erythrocytic stage are often viewed as an anti-disease strategy. By contrast, infection might be completely averted by a vaccine against the liver stage, a pre-erythrocytic stage during which the parasite multiplies 10000-fold within hepatocytes. Sterilizing immunity can be conferred by inoculating humans with irradiated pre-erythrocytic parasites, and a recombinant pre-erythrocytic vaccine partially protects humans from infection. Liver-stage antigen-1, one of a few proteins known to be expressed by liver-stage parasites, holds particular promise as a vaccine. Studies of naturally exposed populations have consistently related immune responses against this antigen to protection.

Report this publication

Statistics

Seen <100 times